Tuberculosis Vaccine

The Central Drug Standard Control Organisation’s (CDSCO) Subject Expert Committee has approved Bharat Biotech International’s proposal to conduct the Phase 2 clinical trial of the Mycobacterium tuberculosis (live attenuated) vaccine to assess the safety and immunogenicity in adolescent and adult populations.
According to a release, the MTBVAC is the first vaccine against TB derived from a human source to begin clinical trials in adults in India.
This vaccine was developed in the laboratory of the University of Zaragoza, in collaboration with Brigitte Gicquel of the Pasteur Institute in Paris.

Dig Deeper: Can the BCG vaccine prevent TB and what is the DOT Programme?

The Food and Agriculture Organization (FAO) has offered its expertise to address the impact of climate change on India’s aquaculture…

The SOWC-2024 report warns of an unprecedented planetary crisis affecting nearly half of the world’s children (one billion), living in…

Prime Minister Modi, during his visit to Guyana for the second India-CARICOM Summit. The summit focused on collaboration in trade,…

Global Access to Nutrition Index 2024It is 5th report assessing 30 of the world’s largest food and beverage (F&B) manufacturers –…

The Delhi Solar Portal was launched to promote rooftop solar panel installations, enabling residents to generate power and reduce electricity…

GM Crops: A Sustainable Solution to Food Security or a Double-Edged Sword? (General Studies III – Science & Technology section…

Welcome to Competex, where Mentoring excellence is our mission. We empower aspiring civil servants to achieve their dreams of serving the nation.

Important Links

Explore Competex